Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter 2025 adjusted earnings of 87 cents, compared to $1.06 a year ago, beating the consensus of 63 cents.

Benzinga

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle

On Friday, Pfizer Inc. (NYSE:PFE) filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk (NYSE:NVO) in a Delaware Court.

Benzinga

How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

International Business Times

Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera

The Independent UK

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Benzinga

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

The Guardian - UK

Pfizer Stock: Is Wall Street Bullish or Bearish?

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart

AI video circulates showing Western leaders making shock revelations

The video was produced by RT and provides a disclaimer about its true nature towards the end.

Euronews

MAGA-Connected Firms Hit Record Profits as Businesses Seek White House Access

Lobbying firms with ties to Donald Trump's MAGA movement are reaping record profits as corporations race to secure influence in Washington, signalling a lucrative new era for political lobbying under Trump 2.0.

International Business Times UK

Trump’s approach to lowering drug costs is raising questions - Roll Call

Several drug pricing experts say without key details, it’s hard to call the individual pharma deals a win for the Trump administration.

Roll Call

COVID-19 vaccines may help some cancer patients fight tumors

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors

The Independent UK

Steve Cohen's Point72 Buys $20M of Surging Biotech Stock That Recently Priced $125M Offering to Advance Myeloma Treatment

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data of a drug to treat myeloma and raised $125 million to fund upcoming trials.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying'

Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative “a good start,” while still acknowledging its limitations.

GOBankingRates

TrumpRx.Gov vs. Mark Cuban’s Cost Plus Drugs: Which Saves Retirees More?

Billionaire celebrity Mark Cuban disrupted the prescription drug industry when he launched the digital pharmaceutical marketplace CostPlus Drugs in 2022. President Donald Trump recently announced a...

International Business Times UK

Pfizer Birth Control Scandal: 1,000 Women Sue Over Brain Tumour Risk After Using Popular Contraceptive

Pfizer faces lawsuits from 1,000 women alleging Depo-Provera birth control caused brain tumours, amid new research showing higher meningioma risk.

Benzinga

Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032

Novo Nordisk A/S (NASDAQ:NVO) is back in the headlines, and not just for its blockbuster weight-loss drug, Ozempic. President Donald Trump recently suggested a dramatic price cut for the drug, sparking some short-term market jitters. But underneath the noise, the stock is cheap at a 14 P/E, and its core…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare…

GOBankingRates

5 Things Retirees Need To Know About the New Trump Drug Program

Will TrumpRx help cut prescription costs for uninsured retirees? Learn how this new drug program could impact retirees' prescription budgets come 2026.

Barchart

Pfizer’s Q3 2025 Earnings: What to Expect

Pfizer is expected to report its third-quarter results next month, and analysts are projecting a double-digit decline in its earnings.

Benzinga

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug

Pfizer Inc. (NYSE:PFE) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.

International Business Times

Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices

AstraZeneca joins Pfizer in cutting US drug prices under Trump's new deal to offer lower costs for Medicaid patients.

International Business Times UK

AstraZeneca Joins Trump's Push to Make Medicines Cheaper — But Why Are Critics Skeptical?

US President Donald Trump announced a deal with UK pharmaceutical AstraZeneca to lower certain drugs for government's Medicaid health plan.

The Guardian - US

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.